Journal of Clinical & Experimental Pathology
Open Access

Abstract

Chondrosarcomas are heterogeneous tumors characterized by production of a cartilaginous matrix. They are the second most common primary bone tumors with currently no effective therapies when unresectable or metastasized. Conventional chondrosarcoma does not respond to existing chemo and radiotherapy modalities, thus development of distal metastases are almost invariably fatal events. Thus, there is a clear need to develop new targeted therapies with high impact on this disease. Deregulated kinase pathways are of growing interest in the field of cancer and have been suggested to have a role in chondrosarcoma. Several investigators have shown that the PI3K/AKT is the most active pathway in chondrosarcoma followed by MEK/ERK pathway. These pathways are crucial to many aspects of cell growth and survival, proliferation, drug resistance, terminal differentiation and apoptosis. Therefore, therapeutic strategies that suppress one or both pathways may prove effective. In this study, we investigated the signaling pathways leading to activation of PI3K/AKT and MEK/ERK in chondrosarcoma and determined the consequences of their inhibition on cell proliferation and survival as well as on tumor growth in xenograft models.

Biography

Email: mohamed.ouzzine@univ-lorraine.fr